Envisagenics

AI-powered RNA therapeutics.

Visit Website →

Overview

Envisagenics has developed SpliceCore®, a cloud-based AI drug discovery platform that uses machine learning to identify new drug targets by analyzing RNA splicing. The platform integrates genomic data with machine learning algorithms to discover disease-specific splicing errors and identify novel therapeutic targets. They are focused on developing treatments for cancer and genetic diseases.

✨ Key Features

  • SpliceCore® AI platform
  • RNA splicing analysis
  • Target discovery
  • Biomarker identification
  • Focus on oncology and genetic diseases

🎯 Key Differentiators

  • Specific focus on RNA splicing as a source of new drug targets.
  • SpliceCore® platform with a large database of splicing events.
  • Combination of AI with deep expertise in RNA biology.

Unique Value: Unlocks a new class of drug targets by using AI to understand and target RNA splicing.

🎯 Use Cases (4)

Discovery of RNA-targeting therapies Target identification for cancer and genetic diseases Understanding the role of RNA splicing in disease Biomarker development

✅ Best For

  • Has established collaborations with major pharmaceutical companies like Bristol Myers Squibb and Biogen.

💡 Check With Vendor

Verify these considerations match your specific requirements:

  • NA

🏆 Alternatives

Deep Genomics Ionis Pharmaceuticals

Focuses on a specific and important area of biology (RNA splicing) that is often overlooked by other platforms.

💻 Platforms

Web API

🔌 Integrations

API

🛟 Support Options

  • ✓ Email Support
  • ✓ Dedicated Support (Enterprise tier)

💰 Pricing

Contact for pricing

Free tier: NA

Visit Envisagenics Website →